BD 252360 - Directigen Meningitis Combo Test Kit Rapid Antigen Detection for Bacterial Meningitis
The BD 252360 Directigen Meningitis Combo is a rapid in vitro diagnostic test kit designed for the qualitative detection of bacterial antigens commonly associated with meningitis in cerebrospinal fluid specimens. Developed by BD, a globally recognized leader in diagnostic microbiology, this test provides fast and reliable results to support early clinical decision-making in suspected meningitis cases.
The Directigen system utilizes immunoassay technology to identify specific bacterial antigens, enabling detection of pathogens such as Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae, and other clinically relevant organisms depending on the panel configuration. The test is designed for ease of use, requiring minimal equipment and delivering results significantly faster than traditional culture-based methods.
Its streamlined format makes it suitable for routine laboratory use, particularly in urgent diagnostic scenarios where rapid identification is critical.
Key Benefits
The BD 252360 Directigen Meningitis Combo provides rapid results, allowing healthcare professionals to initiate timely treatment and improve patient outcomes. Early detection is essential in managing meningitis, and this test significantly reduces diagnostic turnaround time.
The test offers high specificity and sensitivity for targeted pathogens, supporting accurate identification and reducing the risk of false results. Its easy-to-use format simplifies laboratory workflows and minimizes the need for complex instrumentation.
By enabling quick and reliable diagnosis, the product supports effective clinical management and enhances infection control measures.
Compatibility and Applications
The BD Directigen Meningitis Combo is compatible with standard laboratory workflows and requires minimal additional equipment, making it suitable for a wide range of clinical settings.
Typical applications include hospital laboratories, emergency departments, diagnostic centers, and public health laboratories. It is primarily used for testing cerebrospinal fluid samples in patients with suspected bacterial meningitis.
The kit is also valuable in outbreak investigations and situations requiring rapid screening of multiple samples.
Usage Guidelines
Ensure all components are stored according to manufacturer recommendations and brought to room temperature before use. Prepare the cerebrospinal fluid specimen according to standard laboratory procedures.
Apply the sample to the test device as instructed and follow the protocol for incubation and reaction time. Observe the results based on visible reaction indicators, following the interpretation guidelines provided with the kit.
Include appropriate controls to verify test performance. Refer to the manufacturers instructions for detailed procedures and result interpretation.
Certifications and Safety Standards
The BD 252360 Directigen Meningitis Combo is manufactured in compliance with internationally recognized quality standards, including ISO-certified systems and Good Manufacturing Practices. These standards ensure consistent performance, safety, and reliability.
The product is intended for in vitro diagnostic use and aligns with regulatory requirements such as FDA clearance and CE marking where applicable. These certifications confirm adherence to strict safety and performance criteria.
Comparison with Competitor Products
Compared to traditional culture methods, the BD Directigen Meningitis Combo offers significantly faster results, enabling earlier diagnosis and treatment. While culture remains the gold standard, it requires longer processing times, which can delay clinical decisions.
Compared to other rapid antigen tests, BDs product is known for its reliability, ease of use, and consistent performance. Its ability to detect multiple pathogens in a single test provides an advantage over single-target assays.
The combination of speed, accuracy, and convenience makes it a preferred choice for urgent diagnostic applications.
Typical User Profile and Application Scenarios
The BD 252360 Directigen Meningitis Combo is used by microbiologists, laboratory technicians, and clinical diagnosticians involved in infectious disease testing. It is also utilized by emergency and critical care teams requiring rapid diagnostic support.
Typical scenarios include suspected meningitis cases in hospital settings, emergency diagnostics, and public health investigations. The test is particularly valuable in situations where rapid diagnosis can significantly impact patient outcomes.
Best Practices for Use and Maintenance
Store the test kit according to manufacturer guidelines and avoid exposure to extreme temperatures. Use all components within their expiration dates to ensure accuracy.
Follow strict aseptic techniques when handling specimens to prevent contamination. Ensure proper training for personnel performing the test to maintain consistency and reliability.
Dispose of used materials according to biohazard waste regulations. Proper handling and adherence to protocols will ensure optimal performance.
Regulatory and Safety Information
The BD 252360 Directigen Meningitis Combo is intended for professional laboratory use only. Users must follow all biosafety protocols when handling cerebrospinal fluid and other biological samples.
The product complies with regulatory standards for in vitro diagnostic devices, ensuring safe and reliable operation. Proper use and disposal practices are essential to maintain a safe working environment.
How to Order
Ordering the BD 252360 Directigen Meningitis Combo is simple through CIA Medical. Locate the product on the website, add it to your cart, and proceed through the secure checkout process.
For bulk orders, pricing inquiries, or technical assistance, contact CIA Medical customer service at (312) 275-5850. Their team is available to support your diagnostic supply needs with expert guidance.
